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Abstract
Objective
To determine whether serum neurofilament light chain (sNfL) levels are associated with recent
MRI activity in patients with relapsing-remitting MS (RRMS).
Methods
This observational study included 163 patients (405 samples) with early RRMS from the Study
of Early interferon-beta1a (IFN-β1a) Treatment (SET) cohort and 179 patients (664 samples)
with more advanced RRMS from the Genome-Wide Association Study of Multiple Sclerosis
(GeneMSA) cohort. Based on annual brain MRI, we assessed the ability of sNfL cutoffs to
reflect the presence of combined unique active lesions, defined as new/enlarging lesion
compared with MRI in the preceding year or contrast-enhancing lesion. The probability of
active MRI lesions among patients with different sNfL levels was estimated with generalized
estimating equations models.
Results
From the sNfL samples ≥90th percentile, 81.6% of the SET (OR = 3.4, 95% CI = 1.8-6.4) and
48.9% of the GeneMSA cohort samples (OR = 2.6, 95% CI = 1.7-3.9) was associated with
radiological disease activity on MRI. The sNfL level between the 10th and 30th percentile was
reflective of negligible MRI activity: 1.4% (SET) and 6.5% (GeneMSA) of patients developed
≥3 active lesions, 5.8% (SET) and 6.5% (GeneMSA) developed ≥2 active lesions, and 34.8%
(SET) and 11.8% (GeneMSA) showed ≥1 active lesion on brain MRI. The sNfL level <10th
percentile was associated with even lowerMRI activity. Similar results were found in a subgroup
of clinically stable patients.
Conclusions
Low sNfL levels (≤30th percentile) help identify patients with MS with very low probability of
recent radiologic disease activity during the preceding year. This result suggests that in future,
sNfL assessment may substitute the need for annual brain MRI monitoring in considerable
number (23.1%–36.4%) of visits in clinically stable patients.
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Standard clinical follow-up in patients with MS includes
regular assessment for new neurologic signs and symptoms of
MS. However, only a small proportion of CNS lesions,
detected with MRI, are symptomatic.1,2 Thus, MRI is the
most commonly used, sensitive surrogate of subclinical MS
activity.3
Nevertheless, serial MRI follow-up has its limitations, in-
cluding the unsolved challenges of accurate measurement of
brain atrophy, the need for standardized MRI scanning pro-
tocols, cost, and the fact that MRI is frequently not covering
the spinal cord in routine settings.4,5 These limitations, to-
gether with a continued need for an accessible measure of
neurodegeneration, have stimulated a search for new sensitive
biomarkers.
Neurofilaments (NfLs) are the most promising biomarker of
neuroaxonal injury in MS.6–8 Increased concentration of the
NfL light chain in the blood and the CSF are closely associ-
ated with relapse activity, worsening of disability, occurrence
of active MRI lesions and predicts brain and spinal cord
atrophy.9–14 NfL light chain has recently become more ac-
cessible, as reliable methods for quantification of NfL light
chain levels in serum (sNfL) have emerged.10,13
However, its potential role as a new and easily accessible
biomarker of subclinical disease activity has been less studied.
In this context, the role of sNfL in substitution of monitoring
for detection of subclinical disease activity in MRI in certain
clinical scenarios is still to be established.
In this study, we investigated the capacity of sNfL assessment
as a marker of radiologic disease activity, including the sen-
sitivity and specificity of different sNfL cutoffs in identifying
the presence or absence of combined unique active lesions on
brain MRI during the preceding year. We performed this
study in 2 observational cohorts of patients with relapsing-
remitting MS (RRMS): a discovery cohort of patients from
the Study of Early interferon-beta1a (IFN-β1a) Treatment
(SET), and a validation cohort of patients from the Genome-
Wide Association Study of Multiple Sclerosis (GeneMSA).
Methods
Study population
SET cohort
The SET was an investigator-initiated, prospective observa-
tional study that involved 8 centers (NCT01592474) in the
Czech Republic.15–17 Enrollment started in October 2005 and
was completed in July 2009.
In this cohort were included patients with complete sNfL and
MRI data, age 18–55 years, enrollment within 4 months from
the demyelinating event, Expanded Disability Status Scale
(EDSS) score ≤3.5, at least 2 T2 hyperintense lesions on MRI
performed before steroid treatment, and with ≥2 CSF-restricted
oligoclonal bands at the screening visit.
SET patients were originally diagnosed with clinically isolated
syndrome according to theMcDonald 2005 criteria.18 Patients’
diagnosis was reclassified to RRMS based on the 2017
McDonald criteria.19 All patients were treated with IV steroids
following screening and subsequently started the treatment at
baseline with 30 mg of IM IFN-β1a once a week (Avonex).
GeneMSA cohort
Patients were recruited in Basel as part of a prospective
multicenter study initiated in 2003 (GeneMSA).9,20,21
In this cohort were included 179 patients with complete sNfL
and MRI data, who were recruited at the Neurologic Clinic
and Policlinic, University Hospital Basel (Switzerland) be-
tween June 2004 and October 2005.
The GeneMSA cohort consisted of patients with RRMS. A
small proportion (4.5%) of the GeneMSA patients were
originally diagnosed with clinically isolated syndrome
according to theMcDonald 2001 criteria.22 Diagnosis of these
patients was reclassified to RRMS based on the 2017
McDonald criteria.19
Ethical statement
The SET protocol was approved by the Medical Ethics
Committees of the General University Hospital in Prague and
by the local ethical committees in the participating centers,
and all patients gave their written informed consent. All
patients from the GeneMSA cohort provided written in-
formed consent, and the study was approved by the local
ethics committee.
MRI acquisition and analysis
SET cohort
The SET protocol stipulates brain MRI scans at baseline and
at 12, 24, and 36 months, using a standardized protocol
performed on the single 1.5-Tesla scanner (Gyroscan, Phi-
lips). Axial brain acquisitions included fluid-attenuated in-
version recovery, T1-weighted images (T1-WIs), and pre- and
Glossary
DMT = disease-modifying treatment; EDSS = Expanded Disability Status Scale;GeneMSA =Genome-Wide Association Study
of Multiple Sclerosis; IFN-β1a = interferon-beta1a; NfL = neurofilament; RRMS = relapsing-remitting MS; SET = Study of
Early interferon-beta1a (IFN-β1a) Treatment; sNfL = serum neurofilament light chain; T1-WI = T1-weighted image.
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post-contrast T1 spin-echo images. Semiautomated sub-
traction image methodology was used to identify combined
unique active lesions (active lesions later in the text), defined
as current new contrast-enhancing lesions on T1-weighted
scans and new or enlarging lesions on T2-weighted scans
occurred during the preceding year. A new or enlarging lesion
on T2-weighted images was defined as a rounded or oval
lesion (≥3 mm of size) arising from an area previously con-
sidered as normal-appearing brain tissue and/or showing an
identifiable increase in size from a previously stable-appearing
lesion.17 Image analyses were performed at Buffalo Neuro-
imaging Analysis Center, United States.15,17
GeneMSA cohort
Brain MRI scans were performed on all patients at baseline
and then yearly in a 1.5-Tesla scanner (Magnetom Avanto,
Siemens) equipped with a 12-element head matrix coil. MRI
scans were performed on a single scanner at baseline and then
annually over 78 months (median). Axial brain acquisitions
included a double-echo proton density/T2-weighted se-
quence, T1-WI (magnetization prepared rapid acquisition
with gradient echo), and T1 pre- and post-contrast spin-echo
images. Active brain MRI lesions were identified and marked
by consensus reading on simultaneously viewed T2-weighted
and proton density–weighted images. Qualitative analysis for
the presence of gadolinium enhancement was performed on
post-contrast T1-WI. Image analyses were performed in the
Medical Image Analysis Centre in Basel, Switzerland.9 The
details of the MRI acquisition and analysis are provided in
supplementary appendix e-1, links.lww.com/NXI/A233.
Serum neurofilament light
chain measurements
In the SET cohort, serum samples were collected at 12, 24, and
36 months from baseline on the same day as the MRI exami-
nation. In the GeneMSA cohort, serum samples were collected
annually over 78months (median) on the same day as theMRI
examination. In both cohorts, the samples were stored at −80°C
following standard procedures.23 sNfL levels were measured
using a homebrew Single Molecule Array assay at the Univer-
sity Hospital Basel as described previously.13 Interassay coef-
ficients of variation for 3 native serum samples were below 10%
(i.e., 7.8%, 8.8%, and 5.5% for 7.0 pg/mL). The mean intra-
assay coefficient of variation of duplicate determinations for
concentration was 6.4%. One sample (of 405) showed an sNfL
value below 1.3 pg/mL (i.e., the lower limit of quantification)
and was excluded. Measurements were performed on coded
samples by personnel blinded to clinical and MRI data.
Statistical analysis
All analyses were performed using the R statistical software
(R-project.org) and SPSS 22.0 (IBM, Armonk, NY). Statis-
tical analysis of the SET cohort data was performed in the
CORe Unit (University of Melbourne) and of the GeneMSA
cohort data in the Clinical Trial Unit (University of Basel).
sNfL levels were grouped into different categories using age-
specific percentiles derived from a normative data set of
healthy controls. Supplementary table e-1, links.lww.com/
NXI/A234, shows the relationship between sNfL levels and
age-specific sNfL percentiles.13
The sensitivity, specificity, and area under the receiver oper-
ating characteristic curve with their 95% CIs (DeLong
method)24 of different predefined sNfL percentile cutoffs
(sNfL deciles) for detection of ≥1, ≥2, or ≥3 active MRI
lesions during the preceding year were assessed in the pooled
analysis of all available data (figure 1). In other words, we
investigated the capacity of sNfL at a given time point to
identify the presence or absence of combined unique active
lesions on brain MRI, defined as occurrence of current new
contrast-enhancing T1 lesions, new or enlarging T2 lesions
during the previous year. In addition to the pooled analysis of
all available data, in the SET cohort we have separately eval-
uated the sensitivity and specificity of sNfL percentile cutoffs
Figure 1 Study design
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as a marker of MRI activity for each year of follow-up. Next,
conditional probabilities of sNfL percentile ranges for de-
tection of ≥1, ≥2, or ≥3 active MRI lesions were assessed in
both cohorts.
Finally, we estimated the probability of active MRI lesions
among patients with different sNfL levels. sNfL percentile
ranges with similar sensitivity and specificity were combined
into 3 sNfL subgroups (>90th, 31th–90th, and <31th per-
centile). The presence of active MRI lesions was treated as
a binary-dependent and sNfL percentile category as a binary-
independent variable. ORs and 95% CIs were estimated with
logistic generalized estimating equation models adjusted for
age, sex, time point, disability status (only in the sensitivity
analysis), number of relapses during the preceding year, and
current treatment status (with therapies categorized as low
efficacy [dimethyl fumarate, glatiramer acetate, and in-
terferon-β]; high or moderately high efficacy [fingolimod,
mitoxantrone, and natalizumab]; or no disease-modifying
treatment [DMT]). The sNfL between the 31th and 90th
percentile was chosen as the reference category.
The primary analyses were computed in the discovery cohort
(SET) and validated in the validation cohort (GeneMSA). A
sensitivity analysis was completed in a subgroup of clinically
stable patients with no relapses or disability progression during
the preceding year. The Benjamini-Hochberg procedure with p
< 0.05 was used to control the false discovery rate.
Data availability
Anonymized data not published within this article will be
made available by request from any qualified investigator.
Results
Baseline and follow-up clinical characteristics
Table 1 describes demographic, clinical, andMRI characteristics
of the patient cohorts at baseline and during the follow-up. Of
the 220 patients with RRMS enrolled in the SET cohort, 163
had sNfL (405 samples) and MRI follow-up data available ≥1
time point between baseline and 36months. Of the 259 patients
enrolled in the GeneMSA cohort, 179 patients with RRMS had
sNfL (664 samples) and MRI follow-up data available at
baseline and minimum of 1 additional time point. In the SET
cohort, 376 (92.8%) samples were assessed during IFN-β1a
treatment. Of the 120 (67%) patients in the GeneMSA treated
with DMT, the median time on the DMT at baseline was 44.4
months (interquartile range 18.5–66.4 months).
Sensitivity and specificity of sNfL for
identification of brain MRI activity
SET cohort
Higher levels of sNfL correlated with greater numbers of ac-
tive brain MRI lesions (figure 2). sNfL greater than the 90th
percentile was measured in 103 (25.4%) samples and identi-
fied patients with any active brain MRI lesions during the
preceding year with 90% (95% CI = 86%–94%) specificity,
patients with ≥2 active lesions with 90% (95% CI =
86%–93%) specificity, and patients with ≥3 active lesions with
88% (95% CI = 85%–92%) specificity. sNfL ≤30th percentile
was observed in 133 (32.8%) samples and identified patients
with active MRI lesions with 81% (95% CI = 75%–86%)
sensitivity, patients with <2 active lesions with 94% (95%CI =
90%–98%) sensitivity, and patients with <3 active lesions with
99% (95% CI = 99%–100%) sensitivity (table 2). Separate
analysis of time points did not show important differences
(supplementary table e-2, links.lww.com/NXI/A234).
GeneMSA
Similar to the SET cohort, in the GeneMSA cohort, higher
sNfL levels correlated with greater numbers of MRI lesions
(figure 3). sNfL greater than the 90th percentile was found in
184 (27.7%) samples and identified patients with any active
MRI lesions during the preceding year with 80% (95% CI =
77%–85%) specificity, patients with ≥2 active lesions with
79% (95% CI = 77%–83%) specificity, and patients with ≥3
active lesions with 78% (95% CI = 76%–83%) specificity.
sNfL ≤30th percentile was observed in 129 (19.4%) of sam-
ples and identified patients with active MRI lesions with 93%
(95% CI = 89%–96%) sensitivity, patients with <2 active
lesions with 95% (95% CI = 91%–98%) sensitivity, and
patients with <3 active lesions with 92% (95% CI =
87%–97%) sensitivity (table 2). Separate analysis of time
points did not show important differences (supplementary
table e-3, links.lww.com/NXI/A234).
Although there was a trend for slightly lower specificity and
higher sensitivity of sNfL levels in the GeneMSA cohort, 95%
CIs, especially for sensitivity, overlapped considerably be-
tween the 2 cohorts (table 2).
sNfL as a marker of brain MRI activity at the
individual level
SET cohort
At the individual level, sNfL greater than the 90th percentile
indicated a high probability of past MRI activity: 84 of 103
(81.6%) patients developed ≥1 active lesion, 76 (73.8%) de-
veloped ≥2 active lesions, and 66 (64.1%) developed ≥3 active
lesions. In multivariable-adjusted analysis, sNfL above the
90th percentile was associated with a greater probability of
having ≥3 active lesions compared with the 31–90th per-
centile (OR = 7.8; 95% CI = 4.1–14.8; p < 0.0001). Among
the patients with sNfL between the 10th and 30th percentile,
24 (34.8%) developed ≥1 active lesion, 4 (5.8%) developed
≥2 active lesions, and only 1 (1.4%) developed ≥3 active
lesions during the preceding year. Even lower radiologic dis-
ease activity was observed in patients with sNfL <10th per-
centile (table 3). In multivariable-adjusted analysis, sNfL
≤30th percentile was associated with a lower probability of
having ≥3 active lesions compared with the 31–90th
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percentile (OR = 0.05; 95% CI = 0.01–0.3; p < 0.002). Similar
results were observed in the sensitivity analysis of 267
(65.9%) samples from clinically stable patients (table 4).
GeneMSA cohort
sNfL above the 90th percentile was reflective of higher MRI
activity compared with lower sNfL levels. Eighty-six (48.9%)
patients had developed ≥1 active lesion, 69 (39.2%) de-
veloped ≥2 active lesions, and 57 (32.4%) developed ≥3 active
lesions. In multivariable-adjusted analysis, sNfL greater than
the 90th percentile was associated with a greater probability of
having ≥3 active lesions on MRI compared with the 31–90th
percentile (OR = 5.8; 95% CI = 3.2–10.6; p < 0.01). Among
the patients with sNfL between the 10th and 30th percentile,
only 11 (11.8%) developed ≥1 active lesion, 6 (6.5%) de-
veloped ≥2 active lesions, and 6 (6.5%) developed ≥3 active
lesions during the preceding year. Again, lower radiologic
disease activity was observed in patients with sNfL <10th
percentile, where: 3 (8.3%) developed ≥1 active lesion,
1 (2.8%) developed ≥2 active lesions, and 1 (2.8%) developed
≥3 active lesions during the preceding year (table 3). In
multivariable-adjusted analysis, sNfL <31th percentile was
associated with a lower probability of having ≥1 (OR = 0.3;
95% CI = 0.1–0.7; p < 0.01) and ≥2 (OR = 0.3; 95% CI =
0.1–0.9; p = 0.02) active lesions compared with the 31–90th
percentile. The above observations were confirmed in the
sensitivity analysis of 402 (60.5%) measures from clinically
stable patients with no relapses or disability progression
during the previous year (table 4). A sensitivity analysis in
which all models were adjusted also for the EDSS score did
not show considerable differences in the estimates (data not
shown).
Discussion
In this longitudinal study of RRMS, high serum concen-
trations of NfL reflected increased recent radiologic disease
Table 1 Characteristics of the studied cohorts
Characteristics Prague Basel
Total number of patients 163 179
Available sNFL and MRI measures between 0 and 12 mo 149 —
Available sNFL and MRI measures between 12 and 24 mo 131 —
Available sNFL and MRI measures between 24 and 36 mo 125 —
Total available pairs of sNFL and MRI measures 405 664
Females 106 (65.0%) 134 (74.9%)
Age at baseline (y) 28.0 (23–34)a 41.3 (34–48)a
Disease duration at baseline (y) 0.2 (0.2–0.3)a 9.0 (5–17)a
EDSS score at baseline 1.5 (1.5–2.0)a 2.0 (1.5–3.0)a
Follow-up duration (y) 3.0 (3.0–3.0)a 6.5 (2.6–9.2)a
Clinically definite relapsing-remitting MS
At baseline 0 (0%) 171 (95.5%)
At last visit 69 (56.1%) 163 (91.1%)
Clinically stable patients within previous year (all time points)b 267 (65.9%) 402 (60.5%)
sNFL percentile level (all time points) 59 (19–91)a 69 (39–91)a
Proportion of scans with active lesions on MRI over follow-upc 206 (50.9%) 193 (29.1%)
Treatment at baselined
No DMT treatment 0 (0%) 59 (33.0%)
Low efficacy DMT 100 (0%) 118 (65.9%)
High or moderately high efficacy DMT 0 (0%) 2 (1.1%)
Abbreviations: DMT = disease-modifying treatment; EDSS = Expanded Disability Status Scale; sNFL = serum neurofilament level.
a Median and interquartile range.
b Clinically stable defined as an absence of clinical relapse and disability worsening (i.e., increase in the EDSS score).
c Active lesionwas defined as new, newly enlarging, or enhancing lesion on follow-up brainMRI scan comparedwith brainMRI scan during the preceding year.
d Low-efficacy DMT: glatiramer acetate, dimethyl fumarate, and interferons; High or moderately high efficacy DMT: fingolimod, mitoxantrone, and
natalizumab.
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activity defined as occurrence of combined unique new, en-
larging, or contrast-enhancing lesions on brain MRI in the
previous 12 months. On the contrary, low sNfL levels were
associated with negligible MRI activity. Results of the study
were validated in an independent MS cohort and in a sub-
group of clinically stable patients.
Of the patients with activity during the previous 12 months
detected by brain MRI, 41%–47% had sNfL levels exceeding
the 90th percentile. At the individual level, sNfL greater than
the 90th percentile was indicative of high MRI activity: 64.1%
and 32.4% of patients developed ≥3 active lesions, 73.8% and
39.2% of patients developed ≥2 active lesions, and 81.6% and
48.9% of patients showed ≥1 active lesion on MRI in the SET
and GeneMSA cohorts, respectively. However, a considerable
proportion of patients showed high sNfL in the absence of any
reported brain MRI activity (18.4% in the discovery cohort
and 51.1% in the validation cohort). These instances could
represent occasions when the amount of brain inflammatory
activity was below the detection threshold of brain MRI (in-
flammation of normal-appearing white and gray matter),25,26
where inflammation was localized with in the spinal cord or
where the source of sNfL was accelerated global brain tissue
loss due to neurodegenerative processes. In both cohorts,
sNfL greater than the 90th percentile was associated with
approximately 3 times higher probability of having any active
MRI lesion compared with the 31–90th percentile. Patients
with sNfL >90th percentile had also approximately 4 times
higher probability of having ≥2 and 6–8 times higher proba-
bility of having ≥3 active MRI lesions compared with the
31–90th percentile. Importantly, 90% (SET) and 80%
(GeneMSA) of the patients with no detectedMRI activity had
sNfL lower than the 90th percentile.
Based on the observations summarized above, we interpret
the findings of high sNfL (adjusted for age) as an indicator of
a high likelihood of disease activity that should prompt further
investigations with detailed imaging of the whole neuraxis.9 In
these instances, MRI may help explain elevated sNfL, but may
also add clinically relevant information with regard to the
location and extent of lesion activity.27,28 Moreover, sNfL as
a marker is not specific to MS lesion activity but may also
reflect neuroaxonal damage due to other reasons.6 Last but
not least, increased sNfL levels were associated with an in-
creased risk of future disease activity.9,11–14 Therefore,
patients with high sNfL levels without concurrent MRI or
clinical evidence of disease activity should be followed closely
to detect early indicators of treatment failure. Frequent
screening for high (or increasing) sNfL levels may assist
physicians with clinical decision making by providing in-
formation about high probability of recent, ongoing, and fu-
ture subclinical disease activity.
It should be noted that a high sNfL level was strongly asso-
ciated with brain MRI activity, but the sensitivity of the high
sNfL levels for detection of MRI activity during the preceding
year was expectedly lower. This suggests that MRI activity was
reported also in instances with sNfL lower than the 90th
percentile. This can be explained by the time course of sNfL
levels following neuroaxonal injury. sNfL levels peak at 1
month and return to baseline at 6 months after neuroaxonal
injury. Therefore, sNfL levels reflect only recent or ongoing
MRI activity and are not sensitive to neuroaxonal injury oc-
curring before more that 6–9 months.7,14,29
From the clinical perspective, a low sNfL level represented
a very informative finding. sNfL ≤30th percentile was
Figure 2 Proportion of brain MRI scans with 1, 2, or ≥3 active lesions by serum neurofilament percentile subgroups
The SET cohort. SET = Study of Early interferon-beta1a (IFN-
β1a) Treatment
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Table 2 Sensitivity and specificity of serum neurofilament levels for detection of active lesions on brain MRI
sNFL percentile
No. of patients
≥1 Active lesiona ≥2 Active lesionsa ≥3 Active lesionsa
Sensitivity % 95% CI Specificity % 95% CI Sensitivity % 95% CI Specificity % 95% CI Sensitivity % 95% CI Specificity % 95% CI
SET >95th 77 (19.0%) 32 25–38 93 90–97 48 38–54 93 91–97 60 50–70 92 89–95
>90th 103 (25.4%) 41 34–47 90 86–94 56 47–64 90 86–93 71 61–80 88 85–92
>70th 166 (41.0%) 57 51–64 76 69–81 73 66–81 75 69–80 85 77–91 72 66–76
>50th 228 (56.3%) 71 65–78 59 53–66 85 79–91 58 53–64 96 91–99 55 50–61
>30th 272 (67.2%) 81 75–86 47 41–55 94 90–98 46 41–52 99 98–100 42 37–48
>10th 339 (83.7%) 93 89–96 25 20–32 97 94–99 22 18–28 100 NA 21 NA
AUC ROC — 0.74 (0.69–0.79) 0.83 (0.78–0.87) 0.88 (0.85–0.92)
GeneMSA >95th 128 (19.3%) 38 28–41 89 88–93 48 37–53 88 87–92 56 43–63 87 86–91
>90th 184 (27.7%) 47 38–52 80 77–84 56 46–62 79 77–83 65 53–73 78 76–82
>70th 328 (49.4%) 69 62–75 59 54–63 77 69–83 57 53–62 79 69–86 55 51–60
>50th 434 (65.4%) 84 78–89 42 38–47 92 88–96 41 37–45 90 84–96 39 35–42
>30th 535 (80.6%) 93 89–96 24 21–28 95 90–98 23 19–26 92 87–98 21 18–25
>10th 625 (94.1%) 98 96–100 8 5–10 99 98–100 7 5–9 99 97–100 7 5–9
AUC ROC — 0.71 (0.67–0.75) 0.77 (0.72–0.81) 0.77 (0.72–0.83)
Abbreviations: AUC ROC = area under the receiver operating characteristic curve; GeneMSA = Genome-Wide Association Study of Multiple Sclerosis; NA = unable to analyze; SET = Study of Early interferon-beta1a (IFN-β1a)
Treatment; sNFL = serum neurofilament level.
a Active lesion was defined as new, newly enlarging, or enhancing lesion on follow-up brain MRI scan compared with brain MRI scan during the preceding year. All available time points were pooled (repeated measures in the
majority of patients).
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reflective of negligible MRI activity: approximately
0.8%–5.4% of the patients developed ≥3 active lesions,
5.4%–6.0% developed ≥2 active lesions, and 10.9%–29.3%
showed ≥1 active lesion. In both cohorts, sNfL ≤30th per-
centile was associated with approximately 3 times lower
probability of any recent MRI activity compared with the
31–90th percentile. The lower probability of lesion MRI ac-
tivity in patients with sNfL ≤30th percentile levels was also
observed for occurrence of ≥2 and ≥3 activeMRI lesions, with
the relative odds of a clinically significant brainMRI activity in
the SET cohort being extremely low (20 times lower in the
≤30th percentile than the 31–90th percentile). In fact, 81%
(SET) and 93% (GeneMSA) of the patients with any brain
MRI activity had sNfL levels in excess of the 30th percentile,
and 93% (SET) and 98% (GeneMSA) of the patients with any
brain MRI activity had sNfL levels in excess of the 10th
percentile.
Only a very few patients with sNfL ≤30th percentile showed
clinically significant amount of MRI activity, defined as ≥3
(or even ≥2) active MRI lesions.30 In the cohort with
clinically stable disease, the proportion of patients with low
sNfL levels and MRI activity is even lower. We therefore
suggest that assessment of sNfL may substitute the need for
annual brain MRI monitoring in clinically stable patients
with low sNfL levels (≤30th percentile). This constituted
a considerable proportion of the MRI scans from patients
with clinically stable disease included in this study: 36.4% in
the SET and 23.1% in the GeneMSA cohort. However, one
should remember that a small amount of MRI activity (1
active lesion) in the last year can be detected even in
patients with such low sNfL levels. This could be mostly
attributed to only transient increase of sNfL levels following
neuroaxonal injury, which may not correlate with detected
MRI activity, if lesion formation occurred more that 6–9
months ago.7,14,29
In general, the discovery (SET) cohort showed slightly lower
sNfL levels but higher proportion of activeMRI scans (51% vs
29%) than the validation (GeneMSA) cohort. In the Gen-
eMSA cohort, we found a lower number of activeMRI lesions,
which is in agreement with previous research that showed
decreasing incidence of MRI activity over disease course.25
Considering younger age and shorter disease duration of the
SET cohort, a higher proportion of active MRI scans in the
SET cohort is therefore not surprising.
The 2 studied MS cohorts used different scanning protocols
and techniques for detection of active MRI lesions. The
cohorts also differed slightly in terms of the disease burden,
clinical and radiologic disease activity, and sNfL levels over
follow-up. It is therefore reassuring that similar optimal cut-
offs for sNfL were identified in the 2 cohorts. In the SET
cohort, we observed a trend for marginally higher specificity
and lower sensitivity of sNfL than in the GeneMSA cohort,
which was consistent throughout the follow-up. The 95% CIs
for sensitivity overlapped considerably between the 2 cohorts.
One can speculate that these trends were secondary to the
differences in disease burden, disease activity, DMT, or dif-
ferences in MRI protocols. In the preliminary subanalysis of
the GeneMSA cohort, we found a trend for slightly higher
accuracy of sNfL marker of MRI activity in patients with
younger age and short disease duration and lower accuracy of
sNfL cutoffs in patients with older age and long disease du-
ration. These trends remain to be investigated in further
studies and larger cohorts.
Figure 3 Proportion of brain MRI scans with 1, 2, or ≥3 active lesions by serum neurofilament percentile subgroups
The GeneMSA cohort. GeneMSA = Genome-Wide Associa-
tion Study of Multiple Sclerosis.
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Table 3 Predictive values of serum neurofilament percentiles for detection of active lesions on brain MRI
sNFL percentile
range
No. of
samples
Patients with
<1 active lesion
Patients with
≥1 active lesion OR (95% CI)
Patients with <2
active lesion
Patients with
≥2 active lesions OR (95% CI)
Patients with
<3 active lesions
Patients with
≥3 active lesions OR (95% CI)
SET >90th 103 (25.4%) 19 (18.4%) 84 (81.6%) 3.4 (1.8–6.4)a 27 (26.2%) 76 (73.8%) 4.5 (2.5–8.3)a 37 (35.9%) 66 (64.1%) 7.8 (4.1–14.8)a
51–90th 125 (30.9%) 61 (48.8%) 64 (51.2%)
Reference
group
85 (68.0%) 40 (32.0%)
Reference
group
102 (81.6%) 23 (18.4%)
Reference
group31–50th 44 (10.9%) 24 (54.5%) 20 (45.5%) 32 (72.7%) 12 (27.3%) 41 (93.2%) 3 (6.8%)
10–30th 69 (17.0%) 45 (65.2%) 24 (34.8%)
0.4 (0.3–0.7)a
65 (94.2%) 4 (5.8%)
0.1 (0.01–0.3)a
68 (98.6%) 1 (1.4%)
0.05 (0.01–0.3)a
<10th 64 (15.8%) 49 (76.6%) 15 (23.4%) 60 (93.8%) 4 (6.2%) 64 (100.0%) 0 (0%)
GeneMSA >90th 176 (26.5%) 90 (51.1%) 86 (48.9%) 2.6 (1.7–3.9)a 27 (26.2%) 76 (73.8%) 3.5 (2.2–5.5)a 119 (67.6%) 57 (32.4%) 5.8 (3.2–10.6)a
51–90th 258 (38.9%) 182 (70.5%) 76 (29.5%)
Reference
group
85 (68.0%) 40 (32.0%)
Reference
group
233 (90.3%) 25 (9.7%)
Reference
group31–50th 101 (15.2%) 84 (83.2%) 17 (16.8%) 32 (72.7%) 12 (27.3%) 99 (98.0%) 2 (2.0%)
10–30th 93 (14.0%) 82 (88.2%) 11 (11.8%)
0.3 (0.1–0.7)a
65 (94.2%) 4 (5.8%)
0.3 (0.1–0.9)b
87 (93.5%) 6 (6.5%)
0.9 (0.3–2.1)
<10th 36 (5.4%) 33 (91.7%) 3 (8.3%) 60 (93.8%) 4 (6.2%) 35 (97.2%) 1 (2.8%)
Abbreviations: GeneMSA = Genome-Wide Association Study of Multiple Sclerosis; SET = Study of Early interferon-beta1a (IFN-β1a) Treatment; sNFL = serum neurofilament level.
Active lesion was defined as new, newly enlarging, or enhancing lesion on follow-up brain MRI scan compared with brain MRI scan during the preceding year.
All available time points were pooled (repeated measures in the majority of patients).
ORs were estimated by generalized estimating equations adjusted for age, sex, treatment status, time point, and number of relapses during the preceding year.
a p < 0.05 after Benjamini-Hochberg correction.
b p < 0.05.
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Table 4 Predictive values of serum neurofilament percentiles for detection of active lesions on brain MRI in clinically stable patients with MS
sNFL percentile
range No. of
samples
≥1 active lesiona
OR (95% CI)
≥2 active lesionsa
OR (95% CI)
≥3 active lesionsa
OR (95% CI)
Patients with <1
active lesion
Patients with ≥1
active lesion
Patients with <2
active lesion
Patients with ≥2
active lesions
Patients with <3
active lesions
Patients with ≥3
active lesions
SET >90th 53 (19.9%) 14 (26.4%) 39 (73.6%) 2.3 (1.1–4.8)b 20 (37.7%) 33 (62.3%) 3.5 (1.7–7.4)c 25 (47.2%) 28 (52.8%) 6.2 (2.7–14.2)c
51-90th 83 (31.1%) 43 (51.8%) 40 (48.2%)
Reference
group
61 (73.5%) 22 (26.5%)
Reference
group
71 (85.5%) 12 (14.5%)
Reference
group31–50th 34 (12.7%) 15 (44.1%) 19 (55.9%) 23 (67.6%) 11 (32.4%) 31 (91.2%) 3 (8.8%)
10–30th 52 (19.5%) 37 (71.2%) 15 (28.8%)
0.3 (0.2–0.6)c
50 (96.2%) 2 (3.8%)
0.1 (0.05–0.3)c
51 (98.1%) 1 (1.9%)
0.1 (0.01–0.6)b
<10th 45 (16.9%) 35 (77.8%) 10 (22.2%) 42 (93.3%) 3 (6.7%) 45 (100.0%) 0 (0%)
GeneMSA >90th 81 (20.1%) 47 (58.0%) 34 (42.0%) 2.3 (1.2–4.5)c 56 (69.1%) 25 (30.9%) 3.0 (1.5–6.0)c 62 (76.5%) 19 (23.5%) 6.2 (2.4–15.7)c
51–90th 158 (39.3%) 116 (73.4%) 42 (26.6%)
Reference
group
132 (83.5%) 26 (16.5%)
Reference
group
148 (93.7%) 10 (6.3%)
Reference
group31–50th 70 (17.4%) 57 (81.4%) 13 (18.6%) 67 (95.7%) 3 (4.3%) 68 (97.1%) 2 (2.9%)
10–30th 66 (16.4%) 59 (89.4%) 7 (10.6%)
0.3 (0.1–0.8)c
64 (97.0%) 2 (3.0%)
0.2 (0.0–0.7)c
64 (97.0%) 2 (3.0%)
0.5 (0.1–2.1)
<10th 27 (6.7%) 25 (92.6%) 2 (7.4%) 27 (100%) NA 27 (100.0%) NA
Abbreviations: GeneMSA = Genome-Wide Association Study of Multiple Sclerosis; SET = Study of Early interferon-beta1a (IFN-β1a) Treatment; sNFL = serum neurofilament level.
All available time points were pooled (repeated measures in the majority of patients).
Clinically stable patients were defined as those with an absence of clinical relapse and disability progression during the preceding year.
a Active lesion was defined as new, newly enlarging, or enhancing lesion on follow-up brain MRI scan compared with brain MRI scan during the preceding year.
b p < 0.05.
c p < 0.05 after Benjamini-Hochberg correction.
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The ability to detect active MRI lesions is influenced by a va-
riety of technical, rater- and patient-related factors.31,32 There-
fore, variability in the sensitivity of the scanning protocols was
likely. We have mitigated the risk of reporting error for MRI
activity by using also a more rigorous requirement of higher
number of activeMRI lesions as our study outcome.Moreover,
3-dimensional subtracted images after image registration, with
thin-slice thickness, were analyzed by semiautomatic techni-
ques (SET) or by experienced MRI raters (GeneMSA). These
techniques detect considerably higher number of active lesions
compared with imaging used in clinical practice.31,33 Therefore,
in the context of clinical practice, sNfL levels may show a very
good sensitivity even in detection of single active MRI lesion.
This needs to be investigated in future studies.
Second, although the levels of sNfL were interpreted in the
context of its gradual increase with age (through the use of
normative reference data), we did not adjust for other potential
confounders of sNfL. The differences in sNfL levels between
the 2 studied cohort support that in MS, other disease-specific
factors may codetermine sNfL. Among these, disease duration,
time since disease activity, disability, differences in DMT, and
comorbidities would be the likely candidates. Although the
SET patients initiated DMT at baseline, potential effect of
delayed treatment response resulting in decoupling between
sNfL levels at 12months andMRI activity during the preceding
year was not observed. Also, we did not find an effect of dis-
ability on the relationship between sNfL levels and MRI ac-
tivity. Another important question requiring better
understanding is the dynamics of rising and decreasing sNfL
levels following lesion formation and disease activity. Finally,
a large normative database for sNfL in MS patients is needed.
NfL is a promising biomarker of neuroaxonal injury6–8
strongly associated with measures of disease activity in
MS.9–14 Given that a considerable number of patients with
high sNfL levels did not have detectable lesion activity on
brain MRI, further studies are needed to clarify the origin of
increased sNfL in patients with radiologically stable brain
MRI. Based on the results of previous research, we hypoth-
esize that active spinal cord lesions,9 accelerated loss of brain
volume, or subclinical inflammation of normal-appearing
white and gray matter may play a role.25,26 If this hypothesis is
correct, sNfL may, in addition, qualify as a sensitive surrogate
biomarker of inflammation and axonal loss.9
sNfL is a cumulative indicator of neuronal damage over weeks
to months.7,14,29 Future studies are required to investigate the
benefit of more frequent sNfL assessment (e.g., 6-monthly),
which may represent a sensitive and accessible method for
capturing subclinical disease activity in routine follow-up.
Finally, assessment of the relationship between sNfL andMRI
activity in different subgroups is needed to allow generaliza-
tion of the results to the prevalent MS population.
This study, using discovery-validation design in 2 large MS
centers, demonstrates that low levels of sNfL help identify
patients with MS with no clinically relevant radiologic disease
activity. In future, sNfL monitoring may potentially supple-
ment the need for annual brain MRI monitoring in a pro-
portion of patients with clinically stableMS and with low sNfL
levels. Further research is required to understand whether
high sNfL levels in the absence of new or enlarging brain
lesions may signal subclinical disease activity in patients, who
would otherwise be considered stable.
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